A clinical study on efficacy and safety of dopamine replacement therapy for drug-induced parkinsonism

An open-label single-arm study on efficacy and safety of dopamine replacement therapy for drug-induced parkinsonism - An open-label single-arm study on efficacy and safety of dopamine replacement therapy for drug-induced parkinsonism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038397

Enrollment

Registered

2019-10-28

Start date

2019-10-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced parkinsonism

Interventions

Levodopa/carbidopa 300-600mg/day for 2 weeks or more

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with schizophrenia, bipolar disorder, or schizoaffective disorder who receive antipsychotics and/or mood stabilizers. 2. Parkinsonism diagnosed by board-certified neurologists

Exclusion criteria

Exclusion criteria: 1. Orthopedic conditions which preclude quantitative neurological assessments, such as fractures and severe arthralgia. 2. Severe intellectual disabilities which preclude accurate neurological assessments. 3. History of alcohol or other substance abuse. 4. Patients who are already diagnosed as having organic neurological diseases, or whose CT/MRI scans demonstrate cerebrovascular diseases (excluding a few to several numbers of small infarcts or microbleeds) or severe brain atrophy. 5. Patients who take levodopa or dopamine receptor agonists at the baseline assessment.

Design outcomes

Primary

Measure	Time frame
Total score of Movement Disorder Society Unified Parkinson's Disease Rating Scale Part 3	—

Secondary

Measure	Time frame
Total score of Unified Dystonia Scale, Total score of Abnormal Involuntary Movement Scale, Total score of Mini-mental State Examination, Total score of Montogomery-Aperg Depression Rating Scale, Total score of Young Mania Rating Scale, Total score of PANSS-6	—

Countries

Japan

Contacts

Public ContactYoshiyuki Nishio

Tokyo Metropolitan Matsuzawa Hospital Department of Psychiatry and Neurology

nishiokov@gmail.com03-3303-7211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026